MorphoSys AG, an antibody company, and Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company, have formed a strategic alliance to generate antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells. The collaboration agreement provides MorphoSys with access to several proprietary tumor-associated peptides (TUMAPs) discovered using Immatics' XPRESIDENT platform to develol antibody-based therapeutics against these targets in a number of solid and hematological cancers.

XPRESIDENT enables access to antibody targets associated with proteins that are present inside cancer cells. In return, Immatics will be provided with MorphoSys' Ylanthia antibodies against a number of its TUMAPs, with proprietary development rights. The companies will pay each other milestones based on their respective development progress as well as royalties on marketed products. Financial details of the agreement were not disclosed.

Source: MorphoSys AG